Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Pan-tumor × Bevacizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 395 Carcinoma, Non-Small-Cell Lung 206 Breast Neoplasms 172 Ovarian Neoplasms 149 Glioblastoma 142 Neoplasms 116 Rectal Neoplasms 102 Carcinoma, Hepatocellular 101 Colonic Neoplasms 98 Neoplasm Metastasis 95 Brain Neoplasms 88 Lung Neoplasms 75 Fallopian Tube Neoplasms 73 Glioma 63 Carcinoma, Renal Cell 63 Pancreatic Neoplasms 50 Gliosarcoma 41 Melanoma 39 Uterine Cervical Neoplasms 36 Liver Neoplasms 36 Stomach Neoplasms 34 Recurrence 33 Adenocarcinoma of Lung 33 Astrocytoma 28 Endometrial Neoplasms 25 Triple Negative Breast Neoplasms 24 Carcinoma, Ovarian Epithelial 23 Esophageal Neoplasms 21 Kidney Neoplasms 19 Oligodendroglioma 18

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡